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Aims Microvascular dysfunction in hypertrophic cardiomyopathy (HCM) is predictive of clinical decline, however under-
lying mechanisms remain unclear. Cardiac diffusion tensor imaging (cDTI) allows in vivo characterization of myocar-
dial microstructure by quantifying mean diffusivity (MD), fractional anisotropy (FA) of diffusion, and secondary
eigenvector angle (E2A). In this cardiac magnetic resonance (CMR) study, we examine associations between perfu-
sion and cDTI parameters to understand the sequence of pathophysiology and the interrelation between vascular




Twenty HCM patients underwent 3.0T CMR which included: spin-echo cDTI, adenosine stress and rest perfusion
mapping, cine-imaging, and late gadolinium enhancement (LGE). Ten controls underwent cDTI. Myocardial perfu-
sion reserve (MPR), MD, FA, E2A, and wall thickness were calculated per segment and further divided into suben-
docardial (inner 50%) and subepicardial (outer 50%) regions. Segments with wall thickness <_11 mm, MPR >_2.2, and
no visual LGE were classified as ‘normal’. Compared to controls, ‘normal’ HCM segments had increased MD
(1.61 ± 0.09 vs. 1.46 ± 0.07 10-3 mm2/s, P = 0.02), increased E2A (60 ± 9 vs. 38 ± 12, P < 0.001), and decreased
FA (0.29 ± 0.04 vs. 0.35 ± 0.02, P = 0.002). Across all HCM segments, subendocardial regions had higher MD and
lower MPR than subepicardial (MDendo 1.61 ± 0.08 10-3 mm2/s vs. MDepi 1.56 ± 0.18 10-3 mm2/s, P = 0.003,
MPRendo 1.85 ± 0.83, MPRepi 2.28 ± 0.87, P < 0.0001).
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Conclusion In HCM patients, even in segments with normal wall thickness, normal perfusion, and no scar, diffusion is more iso-
tropic than in controls, suggesting the presence of underlying cardiomyocyte disarray. Increased E2A suggests the
myocardial sheetlets adopt hypercontracted angulation in systole. Increased MD, most notably in the subendocar-
dium, is suggestive of regional remodelling which may explain the reduced subendocardial blood flow.
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Introduction
Hypertrophic cardiomyopathy (HCM) is the most common inher-
ited cardiac condition, characterized by unexplained myocardial
hypertrophy in the absence of another cardiac or systemic dis-
ease. Genetic mutations encoding for the sarcomeric proteins
which form the contractile apparatus of cardiomyocytes have
been identified as a cause for the disease.1 Histopathological
changes include cardiomyocyte disarray, interstitial, and perivas-
cular fibrosis; however, how these features develop and affect
prognosis is not fully understood.2 Microvascular dysfunction
(MVD) is a common feature of HCM3 and is thought to be
responsible for ischaemia-mediated myocyte death in HCM, which
ultimately leads to replacement fibrosis and left ventricular (LV)
remodelling.4 Prospective studies have identified the degree of MVD
as an independent predictor of clinical decline and death in HCM
patients; meanwhile, patients can remain asymptomatic with severe
MVD for several years prior to deterioration.5 Hence MVD has been
recognized as a potential target for prevention of disease progression
and heart failure in HCM; but effective disease-modifying therapies
have proved elusive. This may in-part be because of the incomplete
understanding of the pathophysiological process. Abnormal muscle,
abnormal physiology, and abnormal architecture form the basis of

























































































































































pattern of hyperaemic ischaemia. While the cause is thought to be
multifactorial, histological studies to date have failed to demonstrate
any relationship between fibre disarray, fibrosis, and small vessel
disease.6
Cardiac diffusion tensor imaging (cDTI) is a cardiac magnetic res-
onance (CMR) method which allows non-invasive in vivo characteriza-
tion of myocardial microstructure.7,8 Mean diffusivity (MD) measures
the magnitude of diffusion in a given voxel, and previous studies have
shown MD to be increased in areas of interstitial fibrosis in HCM
patients.9 Fractional anisotropy (FA) measures the directional vari-
ability of diffusion in a given voxel. In the context of cardiovascular
disease, FA is thought to provide a composite measure of cardiomyo-
cyte disarray and collagen deposition; initial evidence shows that low
FA values—indicating isotropic diffusion—can be predictive of ad-
verse clinical outcomes such as ventricular arrythmia.10,11 cDTI also
enables calculation of voxel-wise helix angle (HA) and secondary
eigenvector angle (E2A) maps based on the eigenvectors of the diffu-
sion tensors. HA describes local cardiomyocyte orientation and is
classically used to depict their transmurally changing arrangement,12
while absolute E2A reflects the average orientations of laminar sheet-
lets.13 At peak systole, HCM patients have higher global absolute
E2A than controls, indicating their sheetlets adopt significantly
steeper configurations.13,14 Furthermore, their sheetlet mobility is
impaired, so their sheetlets remain in a relatively steeper configur-
ation in diastole than controls.13 While cDTI studies to date have
provided insights into general microstructural abnormalities, their
findings are predominantly based on global difference in parameters
between HCM patients and controls. In order to understand how
microstructure relates to local vascular function, a more regional ap-
proach is required focussing specifically on areas with perfusion
defects, such as the subendocardium. Focused analysis of myocardial
segments which lack typical morphological features such as wall
hypertrophy and scar may also elucidate early microstructural
changes that precede clinical expression of the disease. The purpose
of this study was to examine the associations between perfusion and
cDTI parameters in HCM patients in order to understand the se-
quence of pathophysiology and the interrelation between vascular
function and underlying myocardial microstructure.
Methods
Subject recruitment
HCM patients were prospectively recruited from the inherited cardiomy-
opathy clinic; this was inclusive of probands and relatives. The diagnosis
of HCM was made independently by clinicians in keeping with current
guidelines and based upon imaging including CMR, electrocardiogram,
family history, and genetic testing if possible.15 Inclusion criteria were LV
wall thickness of >_13 mm in >_1 myocardial segment on CMR. Exclusion
criteria were patients with apical HCM, the presence of any contraindica-
tion to CMR, adenosine or gadolinium-based contrast agents, systemic
hypertension, significant valve disease, infiltrative cardiomyopathy, previ-
ous myocardial infarction, or coronary intervention. Healthy volunteers
were enrolled from among students, staff, and alumni of the local univer-
sity. They had no existing medical conditions and were not taking any
regular medication. The study was conducted in accordance with the
Declaration of Helsinki and was approved by the UK National Research
Ethics Service (18/YH/0372, REC 39787). All participants provided writ-
ten informed consent.
CMR acquisition
CMR was performed using a Prisma 3T magnetic resonance imaging
(MRI) scanner (Siemens Healthineers, Erlangen, Germany). Participants
were advised to avoid caffeine for 24 h before the study. The protocol for
HCM patients consisted of full LV coverage by balanced steady-state free
precession (bSSFP) cine data imaging and MOCO bright blood late gado-
linium enhancement (LGE), three matching short-axis slices (base, mid,
and apex) by cDTI, T1 mapping using a Modified Look Locker Inversion
recovery (MOLLI) sequence (native 5(3)3, post-contrast 4(1)3(1)2), and
stress and rest perfusion using free-breathing, motion-corrected
(MOCO) automated in-line perfusion mapping.16 The protocol for
healthy controls consisted of full LV coverage with bSSFP cine-imaging
and cDTI (three slices consisting of base, mid, and apex).
For perfusion imaging, adenosine was infused at a rate of 140mg/kg/
min and increased up to a maximum of 210mg/kg/min according to
haemodynamic and symptomatic response. Inadequate heart rate re-
sponse was defined as <10 bpm in keeping with Society of Cardiovascular
Magnetic Resonance (SCMR) guidelines.17 An intravenous bolus of
0.05 mmol/kg gadobutrol (Gadovist, Leverkusen, Germany) was adminis-
tered at 5 mL/s followed by a 20 mL saline flush using an automated injec-
tion pump (Medrad MRXperion Injection System, Bayer). This is
repeated after a minimum of 10-min interval for rest perfusion acquisi-
tions to ensure equilibration of gadolinium kinetics and that all haemo-
dynamic effects of adenosine had resolved. Following this, a third and final
bolus of 0.05 mmol/kg gadobutrol is given for acquiring LGE imaging.
Blood pressure and heart rate were recorded during adenosine infusion.
Perfusion mapping was performed and implemented on the scanner using
the Gadgetron streaming software image reconstruction framework as
previously described.16
cDTI acquisition
cDTI data were obtained using a second-order motion-compensated
single-shot spin-echo EPI sequence as previously reported.18,19 Data were
acquired whilst free-breathing without respiratory navigation. The effects
of motion were mitigated by acquisition of multiple repetitions and diffu-
sion encoding directions. Acquisition parameters were: TE/TR 77 ms/3 R-
R intervals, field of view 320 121 mm2, matrix size 138 52, in-plane
resolution 2.3 2.3 mm2, 8 mm slice thickness, 8 mm inter-slice gap, and
partial Fourier = 7/8. Scout diffusion-weighted (DW) data were acquired
with diffusion-weighting applied in three orthogonal directions to ensure
data quality. Each full data set comprised b-values of 100 s/mm2 (3 DW
directions, 12 repetitions), and 450 s/mm2 (30 DW directions, 6 repeti-
tions). Cine data were used to define the time from R peak to maximum
systole. The trigger delay was defined as30% of maximum systole.
CMR analysis
On cine, LGE, native T1, and post-contrast T1 images, using cvi42 soft-
ware (Circle Cardiovascular Imaging, Calgary, Canada), LV subendocar-
dial and subepicardial borders were defined by manual planimetry
excluding papillary muscles at end-systole and end-diastole. LV mass,
end-diastolic volumes, end-systolic volumes, and LV ejection fraction
were measured from short-axis cine images. Maximal wall thickness was
measured using a machine learning algorithm as previously described.20
The LV short-axis stack of LGE images was first assessed visually for the
presence of LGE, followed by quantification when LGE was present, as
done in previous studies.21 LGE was defined as areas of signal intensity >_5
SDs from normal myocardium and was expressed both as a percentage
of the segment, and the percentage of LV mass. On T1 maps, a 10% offset























..was applied to subendocardial and subepicardial borders to minimize par-
tial volume effect. Extracellular volume (ECV) was calculated using the
formula ‘myocardial ECV = (1 - haematocrit) (DR1myocardium/DR1blood),
where R1 = 1/T1’, with haematocrit measured from blood tests on the
day of the CMR scan. Global and segmental mean blood flow (MBF) were
calculated inline from the perfusion maps (where each pixel encodes
MBF in mL/g/min). Subendocardial and subepicardial borders were con-
toured automatically using a machine learning approach. Where the LV
outflow tract was included, or partial volume effect meant segments
were too thin to contour, these segments were excluded from further
analysis. Each segment was also further divided into subendocardial (inner
50%) and subepicardial (outer 50%) regions. Myocardial perfusion re-
serve (MPR) was calculated as stress MBF: rest MBF. The 16-segment
American Heart Association (AHA) model22 used for further segmenta-
tion of maximal wall thickness, LGE, T1, and perfusion maps.
cDTI data analysis
Data processing for segmental cDTI analysis was performed using
MATLAB software (MathWorks, MA, USA). Quality control was
undertaken by visual assessment with DW images corrupted by
Figure 1 Flowchart of study enrolment.
....................................................................................................................................................................................................................
Table 1 Characteristics of HCM patients and control subjects
HCM (n 5 20) Controls (n 5 10) P-value
Age (years) 48 ± 18 27 ± 9 <0.01
Male (n) 8/20 4/10 1.00
BSA (m2) 1.9 ± 0.2 2.2 ± 0.4 0.19
Genotype positive 5/20
LV end-diastolic volume index (mL/m2) 78 ± 14 80 ± 10 0.65
LV ejection fraction (%) 67 ± 6 64 ± 4 0.76
LV mass index (g/m2) 81 ± 41 61 ± 16 0.31
Maximal LV wall thickness (mm) 19 ± 5 11 ± 1 <0.001
Left atrial diameter (mm) 43 ± 6 35 ± 2 <0.001
Presence of left ventricular outflow obstruction (n) 6/20
Global T1 (ms) 1323 ± 75
Global ECV (%) 27 ± 4
LGE present (n) 17 (85%)
LGE (% of LV mass) 5.9 ± 10.1
Values are displayed as mean ± standard deviation for continuous variables. Departmental 3.0T scanner reference range for native T1 = 1158 ± 80 ms.
ECV, extracellular volume; HCM, hypertrophic cardiomyopathy; LGE, late gadolinium enhancement; LV, left ventricle























artefact or failed registration omitted from further processing.
Averaged magnitude images were generated from the registered data
by averaging across repetitions, and diffusion tensors were calculated.
Myocardial contours were drawn directly on the cDTI maps: in order
to separate myocardial tissue from blood pool and minimize the
effects of partial voluming, a conservative approach was adopted,
ensuring the borders were drawn within the myocardial wall; cine-
images were used as a visual guide. Tensor eigenvalues, MD, FA, and
absolute E2A maps were assessed both globally and on a segmental
basis. In order to investigate possible explanations for the subendo-
cardial pattern of MVD seen in HCM, each segment of MD and FA
maps were further divided into subendocardial (inner 50%) and sube-
picardial (outer 50%) regions. After data rejection, the number of rep-
etitions for b = 100 s/mm2 were 11.6 ± 1.0, and for b = 450 s/mm2,
5.57 ± 0.96, respectively (inclusive of base and mid slices only; apical
data was excluded from the study due to persistent data quality issues
from unsuppressed fat, signal loss, and suboptimal signal-to-noise
ratio).
Figure 2 Representative maps for a healthy control subject and a patient with hypertrophic cardiomyopathy. Representative mid left ventricular
slices obtained in a healthy control subject (first column) and a patient with hypertrophic cardiomyopathy (HCM) (second column), with schematic
diagrams (third column). On the late gadolinium enhancement (LGE) image, there is evidence of midwall fibrosis in the hypertrophied septal seg-
ments, which corresponds with reduced myocardial blood flow on the stress perfusion maps. On the diffusion tensor imaging maps, in comparison
to the control subject, the HCM patient has increased mean diffusivity, reduced fractional anisotropy, and increased secondary eigenvector angle val-
ues globally, even in segments with normal wall thickness and no scar.
















Subgroup analysis was carried out in order to investigate the cDTI char-
acteristic of HCM segments with different morphological features (i.e.
wall hypertrophy, abnormal perfusion and presence of scar). The normal
range for myocardial blood flow at stress, rest and the perfusion reserve
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Figure 3 Correlations between segmental MD/ECV, MD/MPR, and absolute E2A/wall thickness. Even in the absence of scar, a positive correlation
was noted between mean diffusivity (MD) and extracellular volume (ECV) in the segments of HCM patients (A). Segmental MD also correlated with
myocardial perfusion reserve in corresponding non-scarred segments (B). Segmental absolute secondary eigenvector (E2A) in systole correlated
with the wall thickness of corresponding segments in end-diastole.























































..perfusion imaging as previously reported23 and were as follows: stress
MBF 1.3–3.7 mL/g/min, rest MBF 0.4–1.8 mL/g/min, and MPR 2.2–5.8.
Hence 2.2 was used as a cut-off to define segments with abnormal perfu-
sion. All myocardial segments of HCM patients were subsequently classi-
fied into the following four subgroups: Group 1 (titled ‘normal’) included
segments with normal wall thickness (<_11 mm), normal perfusion re-
serve (>_2.2), and no visual LGE; Group 2 (titled ‘normal thickness, abnor-
mal perfusion’) included segments with normal wall thickness (<_11 mm),
abnormal perfusion reserve (<2.2), and no visual LGE; Group 3 (titled
‘wall hypertrophy, abnormal perfusion’) included segments with abnor-
mal wall thickness (>11 mm), abnormal perfusion reserve (<2.2) and no
visual LGE; and Group 4 (titled ‘scar’) included all segments with visual evi-
dence of LGE.
Statistical analysis
Statistical analysis was performed using the commercially available soft-
ware, Statistical Package for the Social Sciences (SPSS) Statistics 22.0 (IBM
Corporation, Armonk, NY, USA). Normality was assessed through the
Shapiro–Wilk test and variance was assessed by the Levene’s test for
equality of variance. Continuous variables are reported as mean ± stand-
ard deviation. When comparing HCM with healthy volunteers, normally
distributed data were compared using Student’s t-test, non-normally dis-
tributed data by the Kruskal–Wallis test and categorical data were com-
pared using v2 tests. For subgroup and regional comparisons of CMR
parameters between the different groups of HCM segments, to account
for within-subject measurements, a linear mixed effects model was used;
post hoc pairwise testing with Bonferroni correction was used to detect
significant differences between subgroups. Pearson correlation analysis
was used to calculate the correlations between independent variables.
Statistical tests were two-tailed and a P-value of <_0.05 was considered to
be statistically significant.
Results
The study flowchart is shown in Figure 1. Twenty HCM patients
(M:F = 8:12, aged 48 ± 18 years) were included in the study; baseline
characteristics are shown in Table 1. Five of the HCM patients were
gene-positive (MYH7 3, TNNI3 1, MYBPC3 1). The vast ma-
jority (18/20) had septal hypertrophy, while 2 HCM subjects had LV
hypertrophy (LVH) confined to anterior and anterolateral walls. Two
patients were unable to tolerate the side-effects of adenosine, hence
the stress perfusion sequence was omitted. HCM patients had a
mean ejection fraction of 67 ± 6%, mean myocardial mass of
149± 80 g, and mean LGE of 5.9± 10.1%. Ten normal controls
(M:F = 4:6, aged 27± 9 years) underwent cDTI. Of all basal and mid
slice segments, 31/240 segments (13%) were rejected due to imaging
artefacts that remained post data rejection; these image artefacts
resulted from unsuppressed fat, localized signal loss, or low signal–
noise ratio.
Representative LGE, perfusion and cDTI maps are shown in Figure
2. HCM patients had significantly increased global MD (MDHCM
1.62 ± 0.10 10-3 mm2/s vs. MDControls 1.47 ± 0.1 10-3 mm2/s,
P < 0.001), absolute E2A (E2AHCM 64± 10 vs. E2AControls 36 ± 12,
P < 0.001), and significantly lower FA (FAHCM 0.29 ± 0.04
vs. FAControls 0.34± 0.04, P < 0.001) than controls. HCM patients
had significantly lower myocardial blood flow at both stress and
at rest, and significantly lower mean MPR than controls
(stress MBFHCM = 1.4 ± 0.5 mL/g/min, stress MBFControls = 2.5 ±
0.6 mL/g/min, P < 0.001, MPRHCM = 2.1 ± 0.8, MPRControls = 4.0± 0.9,
P < 0.001). MD and ECV are known to increase in areas of scarring
and fibrosis. Even in non-scarred segments, segmental MD correlated
moderately with ECV (P = 0.03, Figure 3A) and MPR in the
.............................. .................................. .................................. ....................
.............................. .................................. ..................................
....................................................................................................................................................................................................................
Table 2 Results from subgroup analysis of HCM patients and healthy controls
Subgroups of segments Controls Group 1 Group 2 Group 3 Group 4 P-value







Variable cut-offs Thickness 11 mm Thickness 11 mm Thickness >11 mm LGE present
MPR 2.2 MPR <2.2 MPR <2.2
No LGE No LGE No LGE
Number of segments (%) 160 (100)a 63 (29) 45 (21) 22 (10) 86 (40)
Wall thickness (mm) 7.6 ± 2.1a 7.8 ± 1.5 8.1 ± 1.6 12.1 ± 2.7 11.3 ± 4.3 <0.001
LGE (%) 12.0 ± 13.2
Native T1 (ms) 1280 ± 13 1325 ± 14 1353 ± 26 1355 ± 56 <0.001
ECV (%) 25.5 ± 1.8 26.8 ± 1.8 25.4 ± 4.1 30.0 ± 2.7 <0.001
Stress MBF (mL/g/min) 2.5 ± 0.6b 1.72 ± 0.08 1.30 ± 0.09 1.27 ± 0.10 1.19 ± 0.08 <0.001
Rest MBF (mL/g/min) 0.6 ± 0.1b 0.66 ± 0.05 0.73 ± 0.05 0.69 ± 0.05 0.68 ± 0.04 0.324
MPR 4.0 ± 0.9b 2.77 ± 0.11 1.81 ± 0.11 1.94 ± 0.14 1.83 ± 0.10 <0.001
MD (10-3mm2/s) 1.46 ± 0.07a 1.61 ± 0.09 1.59 ± 0.08 1.65 ± 0.06 1.67 ± 0.09 <0.001
FA 0.35 ± 0.02a 0.29 ± 0.04 0.28 ± 0.04 0.28 ± 0.02 0.26 ± 0.04 0.019
Absolute E2A () 38 ± 12a 60 ± 9 61 ± 6 69 ± 7 66 ± 6 <0.001
E2A, secondary eigenvector angle; ECV, extracellular volume; FA, fractional anisotropy; LGE, late gadolinium enhancement; MBF, mean blood flow; MD, mean diffusivity; MPR,
myocardial perfusion reserve; MPR, myocardial perfusion reserved.
aDerived from 10 controls recruited in this study.
bDerived from 20 controls as per reference.23

































































































corresponding segment (P = 0.01, Figure 3B), while segmental abso-
lute E2A correlated moderately with wall thickness (P < 0.001, Figure
3C) across all segments. HCM patients had higher global T1 than the
departmental 3.0T scanner reference range (1323 ± 75 vs.
1158± 80 ms).
Subgroup analyses
The results of subgroup analysis are displayed in Table 2 and Figure 4.
Of the 216 analysed segments, 63 (29%) were classified as ‘normal’
(Group 1), 45 (21%) had ‘normal thickness, abnormal perfusion’
(Group 2), 22 (10%) had ‘wall hypertrophy, abnormal perfusion’
(Group 3), and 86 (40%) had ‘scar’ (Group 4). Of note, there were
no hypertrophied segments with normal perfusion. Compared to
controls, ‘normal’ (Group 1) HCM segments had significantly
increased MD (MDHCM Group 1: normal 1.61± 0.09 10-3 mm2/s vs.
MDControls 1.46 ± 0.07 10-3 mm2/s, P = 0.02), increased absolute
E2A (E2AHCM Group 1: normal 60± 9 vs. E2AControls 38± 12,
P < 0.001), and decreased FA (FAGroup 1: normal = 0.29 ± 0.04 vs.
FAControls = 0.35± 0.02, P = 0.002). Out of the normal segments, 81%
were located not in the septum: there was no significant difference in
MD, FA, or E2A between septal and non-septal normal segments.
Compared to the other groups, segments with LGE (Group 4) had
significantly higher MD (MDHCM scar 1.67 ± 0.09 10-3 mm2/s vs.
MDHCM Groups 1–3: no scar 1.58 ± 0.09 10-3 mm2/s, P = 0.001) and sig-
nificantly lower FA (FAHCM Group 4: scar 0.26± 0.04 vs. FAHCM Groups
1–3: no scar 0.30 ± 0.03 P = 0.04). Of note, there was no significant dif-
ference in absolute E2A between hypertrophied segments with and
without scar. Hypertrophied segments (Groups 3 and 4) had signifi-
cantly higher E2A than non-hypertrophied segments (67 ± 7 vs.
61 ± 10, P = 0.016).
Regional variance in perfusion and cDTI
In HCM patients, subendocardial MBF during stress was significantly
lower than subepicardial MBF during stress (1.28 ± 0.65 mL/g/min vs.
1.47 ± 0.56 mL/g/min, P = 0.001) and subendocardial MPR was signifi-
cantly lower than subepicardial MPR (1.85± 0.83 vs. 2.28 ± 0.87,
P < 0.001). Among controls, there was no difference between suben-
docardial and subepicardial MD, however HCM patients had signifi-
cantly higher subendocardial MD than subepicardial MD (MDendo
1.61 ± 0.08 10-3 mm2/s vs. MDepi 1.56± 0.18 10-3 mm2/s,
P = 0.003) as shown in Figure 5. All HCM segments were then subdi-
vided into segments with normal perfusion reserve (MPR >_ 2.2) and
abnormal perfusion reserve (MPR < 2.2). Even segments with normal
perfusion reserve had significantly higher subendocardial MD than
subepicardial MD (MDendo 1.63 ± 0.10 10-3 mm2/s vs. MDepi
1.57 ± 0.11 10-3 mm2/s, P = 0.035). This pattern was also seen in
segments with abnormal perfusion reserve (MDendo
1.62 ± 0.14 10-3 mm2/s vs. MDepi 1.56± 0.12 10-3 mm2/s,
P = 0.003). Subendocardial FA and subepicardial FA did not vary sig-
nificantly in controls (FAendo 0.34± 0.05 vs. FAepi 0.34 ± 0.05,
P = 0.82) or HCM patients (FAendo 0.28± 0.06 vs. FAepi 0.29 ± 0.06,
P = 0.50).
Discussion
In clinical practice, recognizing the phenotypic expression of HCM is
largely limited to the detection of wall hypertrophy and scar forma-
tion. This approach fails to acknowledge several of the underlying
pathophysiological changes, such as MVD that is thought to precede
macroscopic change and yet affect long-term clinical outcome.5,24 In
this prospective study, we compare 20 HCM patients with controls,
use quantitative perfusion to differentiate segments with normal and
abnormal perfusion reserve; and use cDTI to gain insights into under-
lying microstructural differences. The main findings from our study in-
clude: (i) HCM patients had increased MD, increased absolute E2A
and reduced FA compared to controls, even in segments with normal
thickness and normal perfusion reserve; (ii) subendocardial MD was
significantly higher than subepicardial MD, matching the pattern seen
with perfusion imaging. The results from this study could help eluci-
date some early pathophysiological changes that occur in patients
with HCM.
In agreement with the largest quantitative perfusion study of HCM
patients to date,24 our results demonstrate stress MBF and MPR to
Figure 4 Subgroup analysis of cDTI parameters between differ-
ent HCM segments. Segmental mean diffusivity (MD), fractional an-
isotropy (FA), and absolute secondary eigenvector angle (E2A)
values are plotted according to the classification of the segments.
‘Normal’ HCM segments had significantly increased MD, absolute
E2A, and decreased FA than controls.









































be reduced, particularly at the subendocardium; this occurs not only
in hypertrophied and scarred segments but also in segments that
morphologically appear ‘normal’. In fact, 42% of the segments with
wall thickness <11 mm had abnormally low MPR (>2.5 SDs lower
than control cohort range), while all 108 segments with wall thick-
ness >11 mm had abnormally low MPR, supporting the hypothesis
that MVD precedes the development of macroscopic
abnormalities.24,25
Using cDTI, we compared the myocardium of controls with the
myocardial segments of HCM patients that had normal wall thickness,
normal perfusion reserve, and no scar, and still noted several distinct
microstructural differences, suggesting such changes may also pre-
cede the development of macroscopic abnormalities. Firstly, in these
‘normal’ HCM segments, MD was significantly higher than controls,
suggesting water molecules are able to diffuse more freely. In healthy
specimens, cell membranes provide a bio-physiological barrier for dif-
fusion; and previous authors have observed how areas with high MD
correlate with areas of scarring, fibrosis, and increased ECV, where
cellular apoptosis has resulted in the breakdown of cell mem-
branes.9,25 However in the ‘normal’ HCM segments in our study,
ECV values were comparable with normal published values,26 and
there was no evidence of scar with LGE, warranting the exploration
of alternative explanations. On a cellular level, a physical increase in
myocyte size is a hallmark of HCM.2 As previously shown in brain
studies using DW imaging,27,28 an increase in intracellular volume cre-
ates a greater distance between restrictive cell membranes, which
results in increase in MD. Hence the increased subendocardial MD
could be representative of regional myocyte hypertrophy. Various
histological studies have demonstrated subendocardial arterioles in
HCM patients to have smaller cross-sectional lumen area29 and
greater coronary flow resistance30 than controls, and authors have
speculated whether this could be due to compressive effects of re-
gional hypertrophy.31,32 This hypothesis is supported by our finding
of an inverse correlation between subendocardial MD and MPR,
however histological corroboration of this is still lacking. The incre-
mental increase in MD in segments with hypertrophy and scarring in
our cohort correlates with an increase in ECV and LGE; and would
seem to be more attributable to a gradual interstitial fibrotic



































1.49 ± 0.06 1.50 ± 0.06
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Figure 5 Regional MD in controls and HCM patients. In controls, there were no significant differences in subendocardial and subepicardial mean
diffusivity (MD); however, in HCM patients, subendocardial MD was significantly higher than subepicardial MD.

































































































In a recent pre-clinical cDTI study in which rat hearts underwent
pressure-overload LVH, the authors noted regional structural
remodelling in the form of increased dispersion of the HA, most not-
ably at the subendocardium of the specimens.33 They did not report
a subendocardial rise in MD; however, it is worth noting that the
pathophysiology of LVH in HCM is driven by sarcomeric mutations
rather than pressure-overload. In our results, we did not observe a
significant correlation between segmental MD and wall thickness, and
it remains unclear if myocyte hypertrophy directly equates with wall
hypertrophy.
Previous studies have observed absolute E2A to be globally
increased in HCM patients compared to controls suggesting that the
myocardial sheetlets adopt hypercontracted configurations during
systole13,14,26; however, in this study, we demonstrate this to be the
case even in segments with normal thickness and normal perfusion.
Previous authors have speculated whether the compressive deform-
ation of intramyocardial blood vessels during systole can explain the
increased coronary flow resistance in these patients27; however,
results from our study are unable to corroborate this, as absolute
E2A did not vary significantly between segments with normal and ab-
normal perfusion reserve. What we did note was a correlation be-
tween segmental absolute E2A and wall thickness, and E2A was
significantly higher in hypertrophied segments (>11 mm) than non-
hypertrophied segments. It is the dynamic rearrangement of the myo-
cardial sheetlets that drives radial thickening during systole; however,
in HCM patients, sheetlet mobility is impaired so they remain hyper-
contracted and fail to relax in diastole.26 This could explain why seg-
ments with higher absolute E2A in systole had greater LV wall
thickness in end-diastole.
FA reflects the anisotropy of diffusion; studies have shown FA to
correlate inversely with histological measurements of collagen, a
major component of fibrotic tissue.11 This explains the significant re-
duction in FA in segments with scar in our study. Histological analysis
of HCM patients undergoing surgical myomectomy has found that, in
addition to collagen deposition, the specimens also had disorganized
matrix connective tissue.28 The diffusion of water molecules in
enlarged cardiomyocytes within disorganized matrixes is more ran-
dom and isotropic, leading to lower FA values.10 Hence low FA in the
absence of scar is suggestive of underlying cardiomyocyte disarray,
which could explain why FA values were lower in HCM patients than
controls even in segments with no scar. Preclinical studies on mice
have noted cardiomyocyte disarray to be an early response to sarco-
meric mutations, while hypertrophy and fibrosis occur later and are
more secondary responses.6 It remains to be seen if low FA values in
the absence of scar in HCM patients can identify patients who are
genotype-positive but phenotype-negative. A recent study by Ariga
et al.10 demonstrated an association between low FA and ventricular
arrhythmia in HCM patients. The authors used an alternative stimu-
lated echo cDTI sequence which involves longer diffusion times,
hence direct comparison of values cannot be made with our results;
however, the study still highlights the clinical relevance of low FA in
the absence of scar in this population.
Limitations
The study sample is relatively small, but in keeping with similar stud-
ies.14 cDTI volunteers were not age-matched to the HCM subjects;
however, it is yet to be established whether DTI parameters change
with age. The ECV, MPR, and LGE of healthy volunteers were not
obtained, as it was not felt ethically justifiable to administer contrast
in this cohort. Conclusions drawn from this study are based on cor-
relations with published evidence and other cardiac MRI markers,
whereas validation with histological specimens would be preferable.
cDTI in a novel technique still under validation: as such the accuracy
of DTI measurements in relation to the impact of partial volume
effects requires further investigations on a large multicentre scale.
Conclusion
By using a combination of quantitative perfusion and cDTI, our results
demonstrate a complex relationship between abnormal anatomy, ab-
normal physiology, and abnormal microstructure in HCM patients,
the concomitant effects of which may help explain the underlying
mechanisms behind MVD. Even in segments which lack phenotypic
features of HCM, diffusion is more isotropic than controls, the myo-
cardial sheetlets adopt hypercontracted configurations in mid-
systole, and the MD is higher particularly in the subendocardium, indi-
cating regional remodelling which may impact on MPR. These findings
highlight some of the microstructural changes that may precede
macroscopic abnormalities and could prove useful for early detection
of the disease, family screening and early phenotyping. Further larger
studies will be needed to validate these findings.
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